- Home
- KRMD vs KLRS Comparison
KRMD vs KLRS Comparison
Compare KRMD & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- KLRS
- Stock Information
- Founded
- KRMD 1980
- KLRS 2019
- Country
- KRMD United States
- KLRS United States
- Employees
- KRMD N/A
- KLRS N/A
- Industry
- KRMD Medical/Dental Instruments
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRMD Health Care
- KLRS Health Care
- Exchange
- KRMD Nasdaq
- KLRS Nasdaq
- Market Cap
- KRMD 134.3M
- KLRS 129.0M
- IPO Year
- KRMD N/A
- KLRS N/A
- Fundamental
- Price
- KRMD $2.79
- KLRS $3.00
- Analyst Decision
- KRMD Strong Buy
- KLRS Buy
- Analyst Count
- KRMD 4
- KLRS 1
- Target Price
- KRMD $4.63
- KLRS N/A
- AVG Volume (30 Days)
- KRMD 131.4K
- KLRS 50.6K
- Earning Date
- KRMD 05-07-2025
- KLRS 05-14-2025
- Dividend Yield
- KRMD N/A
- KLRS N/A
- EPS Growth
- KRMD N/A
- KLRS N/A
- EPS
- KRMD N/A
- KLRS N/A
- Revenue
- KRMD $35,083,740.00
- KLRS N/A
- Revenue This Year
- KRMD $18.16
- KLRS N/A
- Revenue Next Year
- KRMD $14.60
- KLRS N/A
- P/E Ratio
- KRMD N/A
- KLRS N/A
- Revenue Growth
- KRMD 19.65
- KLRS N/A
- 52 Week Low
- KRMD $1.86
- KLRS $2.65
- 52 Week High
- KRMD $5.05
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- KRMD 48.68
- KLRS N/A
- Support Level
- KRMD $2.63
- KLRS N/A
- Resistance Level
- KRMD $2.97
- KLRS N/A
- Average True Range (ATR)
- KRMD 0.19
- KLRS 0.00
- MACD
- KRMD -0.03
- KLRS 0.00
- Stochastic Oscillator
- KRMD 24.44
- KLRS 0.00
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.